Phase 3 trial compares pembrolizumab with or without lenvatinib in PD-L1+ recurrent/metastatic HNSCC

This was a phase 3 randomized controlled trial investigating pembrolizumab with or without lenvatinib as first-line treatment. The study enrolled 511 patients with PD-L1 selected recurrent or metastatic head and neck squamous cell carcinoma. Participants were randomized to receive either pembrolizumab plus lenvatinib or pembrolizumab plus placebo. The primary outcomes were objective response rate, progression-free survival, and overall survival, all assessed by blinded independent central review using RECIST 1.1 criteria. The specific results for these efficacy endpoints, including response rates, survival data, and statistical significance, are not reported in the provided information. No safety or tolerability data, including rates of adverse events, serious adverse events, or treatment discontinuations, are available from this summary. The trial's follow-up duration and specific secondary outcomes were not detailed. A key limitation is the absence of reported efficacy and safety results, which prevents any assessment of the combination's benefit-risk profile. The study was funded by Merck Sharp & Dohme LLC. Until full peer-reviewed publication of the trial data, including mature survival outcomes and detailed safety analysis, no conclusions can be drawn regarding the clinical utility of adding lenvatinib to pembrolizumab in this setting.

Researchers conducted a Phase 3 clinical trial to test a new combination of drugs for people with advanced head and neck cancer that has returned or spread. The study involved 511 patients whose cancer had a specific marker called PD-L1. They compared the standard immunotherapy drug pembrolizumab to pembrolizumab plus an additional drug called lenvatinib.

The trial measured whether tumors shrank, how long patients lived without their cancer getting worse, and overall survival. However, the detailed results for these main goals have not been released to the public yet. We do not know if the combination worked better or if it caused more side effects.

Because the results are not available, it is impossible to draw any conclusions about the treatment's benefits or risks. The study was funded by the company that makes the drugs. For now, patients should know this research is ongoing, and the standard of care has not changed based on this unreported data.